基于图形的深度学习模型在预测早期阿尔茨海默氏症的预测中
概括
从静止状态fMRI获得的功能连接性比使用深度学习预测阿尔茨海默病进展的时间点更有效. 一个具有自我聚类的新型图形变压器提高了大脑网络中的分类准确性.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 神经学 神经学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,是最常见的与年龄相关的认知障碍.
- 早期准确预测AD进展对于及时干预和管理至关重要.
- 休息状态功能磁共振成像 (rs-fMRI) 提供了一种非侵入性方法来评估大脑功能和连接性.
研究的目的:
- 评估 rs-fMRI 时间点与功能连接 (FC) 对阿尔茨海默病进展的预测能力.
- 开发和评估一个先进的图形变压器模型,具有自我聚类,以改进AD预测.
- 在AD分类的深度学习模型中比较不同rs-fMRI数据表示的有效性.
主要方法:
- 利用深度学习和基于图形的模型,包括一种具有自我聚类的新型图形变压器变体.
- 进行了rs-fMRI时间序列数据和衍生功能连接矩阵的比较分析.
- 应用模型用于阿尔茨海默氏病神经成像计划 (ADNI) 数据集,其中包括830名受试者.
主要成果:
- 功能连接 (FC) 对基于变压器的模型的原始rs-fMRI时间点显示出明显更高的预测效用.
- 拟议的图形变压器包含一个自我聚类的注意力模块,可以提高AD预测大脑网络分类的准确性.
- 与预测模型的FC指标相比,rs-fMRI时间点内的时间信息提供了有限的附加值.
结论:
- 功能连接是比rs-fMRI时间点更强大的生物标志物,用于基于深度学习的阿尔茨海默病进展预测.
- 在图形转换器中开发的基于集群的注意力机制有效地提高了AD中大脑网络变化的分类.
- 这些发现为推进基于神经成像的阿尔茨海默病诊断和预后工具提供了宝贵的见解.
相关概念视频
Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Dementia
87
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
87
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145


